[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342965-105":59,"doc-detail-342965-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","down-regulation-of-slc14a1-in-prostate-cancer-activates-cdk1ccnb1-and-mtor-pathways-and-promotes-tumor-progression","Down-regulation of SLC14A1 in prostate cancer activates CDK1/CCNB1 and mTOR pathways and promotes tumor progression","","Prostate cancer progression is linked to reduced expression of the urea transporter SLC14A1. Bioinformatics and experimental results show that SLC14A1 is significantly down-regulated during PCa progression, driven by hypermethylation of the SLC14A1 promoter, and that low expression with promoter hypermethylation correlates with poor patient prognosis. Restoring SLC14A1 expression suppresses CDK1/CCNB1 and mTOR/MMP-9 signaling, inhibiting proliferation and metastasis. SLC14A1 is enriched in prostate basal-type cells, suggesting it as a novel indicator and suppressor of tumor progression.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/down-regulation-of-slc14a1-in-prostate-cancer-activates-cdk1ccnb1-and-mtor-pathways-and-promotes-tumor-progression/342965/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/down-regulation-of-slc14a1-in-prostate-cancer-activates-cdk1ccnb1-and-mtor-pathways-and-promotes-tumor-progression/342965.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does SLC14A1 play in prostate cancer progression?","Question",{"text":112,"@type":113},"SLC14A1 expression decreases as prostate cancer progresses, and low expression is associated with poor prognosis. SLC14A1 overexpression suppresses proliferation and metastasis, indicating an inhibitory role in progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is reduced SLC14A1 expression caused in PCa?",{"text":117,"@type":113},"The study attributes decreased SLC14A1 expression to hypermethylation of the SLC14A1 promoter region.",{"name":119,"@type":110,"acceptedAnswer":120},"Which signaling pathways are affected by SLC14A1 overexpression?",{"text":121,"@type":113},"SLC14A1 overexpression suppresses the CDK1/CCNB1 pathway and the mTOR/MMP-9 signaling pathway.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342965,1790218584,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nDown‑regulation ofSLC14A1 in prostate cancer activates CDK1/ CCNB1 and mTOR pathways and promotes tumor progression  \nJianbin Ma1,3, Kaihua Xue2,3, Yifan Jiang2, Xinyang Wang2, Dalin He1,2* & Peng Guo2*  \nProstate cancer (PCa) is the most common cancer among men in the United States and the leading cause of cancer‑related death. The Solute Carrier Family 14 Member 1 (SLC14A1) is a member of urea transporters which are important for the regulation of urine concentration. However, the physiological significance of SLC14A1 in PCa still remains unclear. In the present study, via bioinformatics analysis and experiments, we found that expression ofSLC14A1 is significantly decreased in PCa progression, which could be attributed to hypermethylation on SLC14A1 promoter region. Moreover, its low expression and hypermethylation on SLC14A1 promoter are closely related to the poor prognosis of PCa patients. On the other hand, overexpression ofSLC14A1 inhibited cell proliferation and metastasis while its overexpression also suppressed CDK1/CCNB1 pathway and mTOR/MMP‑9 signaling pathway. Additionally, SLC14A1 expression is enriched in prostate basal‑type cells. In summary, our study indicates that its low expression level and promoter hypermethylation of SLC14A1 may represent novel indicators for PCa progression and prognosis, and SLC14A1 could inhibit the progression of PCa.  \nProstate cancer (PCa) is the most common cancer among men in the United States and the second leading cause of cancer-related death1. Although localized disease is associated with a good prognosis, the 5-year survival rate for patients with metastatic PCa has dropped dramatically to 30%2. For decades, androgen deprivation therapy (ADT) has been the first treatment choice for patients with PCa. However, many patients, who initially respond, develop resistance to ADT and eventually develop to metastatic castration resistant PCa (mCRPC) . Several sequencing studies have identified various PCa drivers, such as loss of TP53, amplification ofc-MYC and MYCN, and alterations in PI3K, WNT and/or DNA repair pathways were enriched in advanced PCa3. Nevertheless, the exact causes for the development of PCa are still unclear. Thus, there is an urgent need to develop novel diagnostic and therapeutic approaches to better understand the development of PCa and provide novel targets for treatment.  \nThere are several mechanisms of gene downregulation in PCa, mainly including gene deletion and epigenetic modifications. As we known, frequent deletions, such as loss of PTEN, TP53 and RB1, occur in PCa progression4,5, and PCa shows poor outcomes with loss of the potent tumor suppressors described above6. Some other genes including APC, ATM, BRCA1/BRCA2, CHD1, ERF, KMT2A, SETD2 are deleted to varying degrees in the progression and development of PCa4. DNA methylation, one of the important epigenetic modifications, plays essential roles in tumor initiation and progression of PCa. It has been reported that the methylation status of specific genes could be considered as potential tumor biomarker for the early diagnosis and prognosis of patients with PCa7. Meanwhile, hypermethylation of CpG islands is an important mechanism for gene silencing and downregulation in PCa8. Most importantly, hypermethylation of DNA promoter is not only associated with poor outcomes, clinical stage or pathological grade of PCa patients, but also it contributes to the abilities of invasiveness and metastasis of prostate tumors9. In PCa, several genes with promoter methylation have been identified, such as GSTP1, CDKN2A andAPC7. However, we still need to further explore the significance of DNA methylation in PCa progression.  \nThere are three epithelial cell types in the prostate gland, including luminal cells, which express CK8, CK18 and high levels ofAR, basal cells, which express CK14 (encoded by KRT14), p63 and CK5 (encoded by KRT5),  ","cbCairND9AZBFXTa","https://ap.wps.com/l/cbCairND9AZBFXTa","pdf",5734057,15,"English","# Background\n## Epidemiology and therapeutic challenge\n## Genetic alterations and need for new targets\n## Epigenetic downregulation and DNA methylation in PCa\n## Prostate epithelial cell types and basal-cell subpopulations\n# SLC14A1 in cancer\n## Function as a urea transporter\n## Genomic location and disease associations","[{\"question\":\"What role does SLC14A1 play in prostate cancer progression?\",\"answer\":\"SLC14A1 expression decreases as prostate cancer progresses, and low expression is associated with poor prognosis. SLC14A1 overexpression suppresses proliferation and metastasis, indicating an inhibitory role in progression.\"},{\"question\":\"How is reduced SLC14A1 expression caused in PCa?\",\"answer\":\"The study attributes decreased SLC14A1 expression to hypermethylation of the SLC14A1 promoter region.\"},{\"question\":\"Which signaling pathways are affected by SLC14A1 overexpression?\",\"answer\":\"SLC14A1 overexpression suppresses the CDK1/CCNB1 pathway and the mTOR/MMP-9 signaling pathway.\"}]","Down-regulation of SLC14A1 in prostate cancer activates CDK1/CCNB1 and mTOR pathways and promotes tumor progression | PDF",1790049167,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f332ae62d494a4b32f7474e9e1443e4c.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e409fe01af8511c96e6dc1dbc79805b.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b76d5f275f9dcf5546a54dfc96c6b69.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc8b9de7dee6e9fe0fd39e5f2c59763d.webp",980,1287]